StockData
aTYR PHARMA INC logo

aTYR PHARMA INC (ATYR) stock

ATYRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$4.99−0.25 (-4.77%)

Close on Nov 17, 2026Market cap $489.46MP/E –Yield –

aTYR PHARMA ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

aTYR PHARMA's ebitda for the twelve months ending Jun 30, 2026 was -$63.20M. For fiscal 2025 it was -$76.96M. The highest annual figure on record is -$15.34M in fiscal 2020.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$76.96M–
FY2024Dec 31, 2024-$67.21M–
FY2023Dec 31, 2023-$54.33M–
FY2022Dec 31, 2022-$46.17M–
FY2021Dec 31, 2021-$33.54M–
FY2020Dec 31, 2020-$15.34M–
FY2019Dec 31, 2019-$22.34M–
FY2018Dec 31, 2018-$32.07M–
FY2017Dec 31, 2017-$46.43M–
FY2016Dec 31, 2016-$57.04M–
FY2015Dec 31, 2015-$46.75M–
FY2014Dec 31, 2014-$22.73M–
FY2013Dec 31, 2013-$18.83M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$10.71M–
Q1 FY2026Mar 31, 2026-$11.27M–
Q4 FY2025Dec 31, 2025-$14.63M–
Q3 FY2025Sep 30, 2025-$26.58M–
Q2 FY2025Jun 30, 2025-$20.15M–
Q1 FY2025Mar 31, 2025-$15.61M–
Q4 FY2024Dec 31, 2024-$15.65M–
Q3 FY2024Sep 30, 2024-$17.97M–
Q2 FY2024Jun 30, 2024-$17.14M–
Q1 FY2024Mar 31, 2024-$16.46M–
Q4 FY2023Dec 31, 2023-$15.78M–
Q3 FY2023Sep 30, 2023-$12.44M–
Q2 FY2023Jun 30, 2023-$13.40M–
Q1 FY2023Mar 31, 2023-$12.71M–
Q4 FY2022Dec 31, 2022-$7.91M–
Q3 FY2022Sep 30, 2022-$13.44M–
Q2 FY2022Jun 30, 2022-$12.52M–
Q1 FY2022Mar 31, 2022-$12.30M–
Q4 FY2021Dec 31, 2021-$8.53M–
Q3 FY2021Sep 30, 2021-$7.61M–
Q2 FY2021Jun 30, 2021-$10.32M–
Q1 FY2021Mar 31, 2021-$7.08M-451.2%
Q4 FY2020Dec 31, 2020-$4.81M–
Q3 FY2020Sep 30, 2020-$6.38M–
Q2 FY2020Jun 30, 2020-$6.16M–
Q1 FY2020Mar 31, 2020$2.02M–
Q4 FY2019Dec 31, 2019-$5.81M–
Q3 FY2019Sep 30, 2019-$5.34M–
Q2 FY2019Jun 30, 2019-$5.48M–
Q1 FY2019Mar 31, 2019-$5.71M–
Q4 FY2018Dec 31, 2018-$5.78M–
Q3 FY2018Sep 30, 2018-$6.49M–
Q2 FY2018Jun 30, 2018-$9.77M–
Q1 FY2018Mar 31, 2018-$10.04M–
Q4 FY2017Dec 31, 2017-$11.04M–
Q3 FY2017Sep 30, 2017-$10.68M–
Q2 FY2017Jun 30, 2017-$11.73M–
Q1 FY2017Mar 31, 2017-$12.99M–
Q4 FY2016Dec 31, 2016-$12.31M–
Q3 FY2016Sep 30, 2016-$13.64M–

More aTYR PHARMA figures

See a number that looks wrong?